Evidence map›Paper›PMID 35228310›Full record

ArticleeNeuro

Minimizing the

Sarah R Ocañas, Kevin D Pham, Harris E Blankenship, Adeline H Machalinski, Ana J Chucair-Elliott, Willard M Freeman

Open access · goldAbstract read
In one paragraph

Article in eNeuro. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed
5.9field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 57 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Sarah R OcañasGenes & Human Disease Program, Oklahoma Medical Research Foundation, Oklahoma City, OK 73104.
Kevin D PhamGenes & Human Disease Program, Oklahoma Medical Research Foundation, Oklahoma City, OK 73104.
Harris E BlankenshipGenes & Human Disease Program, Oklahoma Medical Research Foundation, Oklahoma City, OK 73104.ORCID 0000-0001-7570-4895
Adeline H MachalinskiGenes & Human Disease Program, Oklahoma Medical Research Foundation, Oklahoma City, OK 73104.
Ana J Chucair-ElliottGenes & Human Disease Program, Oklahoma Medical Research Foundation, Oklahoma City, OK 73104.
Willard M FreemanGenes & Human Disease Program, Oklahoma Medical Research Foundation, Oklahoma City, OK 73104 bill-freeman@omrf.org.
Oklahoma Medical Research Foundation · US

Funding

Targeted DNA Methylation and Mitochondrial Heteroplasmy CoreP30AG050911 · NIA · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI Veronica Galvan · 2015 to 2026
$13.9M
P30-CENTER CORE GRANT FOR VISION RESEARCHP30EY021725 · NEI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI Michelle C Callegan, MICHAEL H ELLIOTT · 2011 to 2026
$10.5M
GEROSCIENCE TRAINING PROGRAM IN OKLAHOMAT32AG052363 · NIA · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI Benjamin Francis Miller, William Edmund Sonntag · 2017 to 2026
$3.6M
Sex divergence and cell specificity of age-related hippocampal DNA modificationsR01AG059430 · NIA · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI FREEMAN, WILLARD M · 2019 to 2023
$2.7M
A novel approach to understand a mechanism of proteostatic decline with agingR56AG067754 · NIA · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI MILLER, BENJAMIN FRANCIS · 2020 to 2020
$768k
Epigenetic regulation of sexually divergent neuroinflammation with brain aging and Alzheimer's diseaseF31AG064861 · NIA · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI OCANAS, SARAH RENEE · 2019 to 2021
$94k
Dynamics of the brain epigenome with agingI01BX003906 · VA · OKLAHOMA CITY VA MEDICAL CENTER · PI FREEMAN, WILLARD M · 2018 to 2021
–
BLRD VA I01 BX003906BLRD VA I01 BX005592BLRD VA IK6 BX006033NEI NIH HHS P30 EY021725NIA NIH HHS F31 AG064861NIA NIH HHS P30 AG050911NIA NIH HHS R01 AG059430NIA NIH HHS R56 AG067754NIA NIH HHS T32 AG052363
6 · The paper itself

Abstract

Modern molecular and biochemical neuroscience studies require analysis of specific cellular populations derived from brain tissue samples to disambiguate cell type-specific events. This is particularly true in the analysis of minority glial populations in the brain, such as microglia, which may be obscured in whole tissue analyses. Microglia have central functions in development, aging, and neurodegeneration and are a current focus of neuroscience research. A long-standing concern for glial biologists using

Indexed as

MicrogliaTranscriptomeAnimalsCell SeparationFlow CytometryMiceNeurogliabraincell sortingex vivo activationmethodsmicrogliatranscriptome

Identifiers

PMID35228310
PMCPMC8970438
OpenAlexW4214580009

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.